Scarica l'app Stockscreener
38.97
2.04%
0.78
Dopo l'orario di chiusura:
39.06
0.09
+0.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$38.19
Aprire:
$38.25
Volume 24 ore:
2.60M
Relative Volume:
1.07
Capitalizzazione di mercato:
$5.39B
Reddito:
$181.74M
Utile/perdita netta:
$-143.97M
Rapporto P/E:
-28.04
EPS:
-1.39
Flusso di cassa netto:
$9.60M
1 W Prestazione:
+8.07%
1M Prestazione:
+32.46%
6M Prestazione:
+243.35%
1 anno Prestazione:
+84.69%
Intervallo 1D:
$38.19
$40.29
Intervallo di 1 settimana:
$34.61
$40.29
Portata 52W:
$9.57
$40.29
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Confronta ARWR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
38.97 | 4.97B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-05 | Iniziato | Goldman | Neutral |
| 2023-12-04 | Iniziato | BofA Securities | Buy |
| 2023-09-19 | Iniziato | Citigroup | Neutral |
| 2023-07-21 | Iniziato | TD Cowen | Outperform |
| 2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Ripresa | Goldman | Buy |
| 2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-19 | Iniziato | Citigroup | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Iniziato | Goldman | Neutral |
| 2020-01-21 | Iniziato | SVB Leerink | Underperform |
| 2019-12-13 | Iniziato | Oppenheimer | Perform |
| 2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-27 | Reiterato | B. Riley FBR | Buy |
| 2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
| 2019-10-03 | Iniziato | Robert W. Baird | Outperform |
| 2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Arrowhead Pharmaceuticals stock hits 52-week high at 39.42 USD By Investing.com - Investing.com Nigeria
(ARWR) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Is Arrowhead Pharmaceuticals Inc. showing signs of accumulationEarnings Trend Report & AI Enhanced Trading Alerts - newser.com
Applying Wyckoff theory to Arrowhead Pharmaceuticals Inc. stockPortfolio Value Summary & Accurate Intraday Trade Tips - newser.com
Is Arrowhead Pharmaceuticals Inc. stock attractive for growth ETFs2025 Momentum Check & Expert Curated Trade Setup Alerts - newser.com
Short interest data insights for Arrowhead Pharmaceuticals Inc.July 2025 News Drivers & Stock Market Timing Techniques - newser.com
What Fibonacci levels say about Arrowhead Pharmaceuticals Inc. reboundJuly 2025 Action & Community Consensus Picks - newser.com
What to expect from Arrowhead Pharmaceuticals Inc. in the next 30 daysPortfolio Value Report & Intraday High Probability Setup Alerts - newser.com
How buybacks impact Arrowhead Pharmaceuticals Inc. stock valueTrade Analysis Summary & Verified Stock Trade Ideas - newser.com
Advanced analytics toolkit walkthrough for Arrowhead Pharmaceuticals Inc.Quarterly Market Review & Long-Term Growth Portfolio Plans - newser.com
Arrowhead CFO Ken Myszkowski to retire, Daniel Apel to succeed - MSN
Sector ETF performance correlation with Arrowhead Pharmaceuticals Inc.2025 Risk Factors & Low Risk High Reward Ideas - newser.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Arrowhead Pharmaceuticals Inc a good long term investmentSector Performance Review & Free Double Digit Growth Tips - earlytimes.in
Arrowhead Pharmaceuticals Inc HDP1 Stock Analysis and ForecastMACD Histogram Signals & Budget Friendly Capital Growth - earlytimes.in
Arrowhead Pharmaceuticals Inc. stock chart pattern explainedEarnings Recap Summary & Community Supported Trade Ideas - newser.com
Pinion Investment Advisors LLC Has $1.19 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
Will Arrowhead Pharmaceuticals Inc. see short term momentum2025 Price Targets & Daily Market Momentum Tracking - newser.com
Has Arrowhead Pharmaceuticals Inc. found a price floorJuly 2025 Fed Impact & Low Drawdown Investment Strategies - newser.com
Can Arrowhead Pharmaceuticals Inc. stock deliver surprise earnings beatJuly 2025 EndofMonth & Real-Time Sentiment Analysis - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals (ARWR): Valuation Insights Following First-in-Class RNAi Therapy Trial Application - Sahm
Is Arrowhead Pharmaceuticals Inc. still worth holding after the dipM&A Rumor & Consistent Growth Stock Picks - newser.com
What technical models suggest about Arrowhead Pharmaceuticals Inc.’s comebackM&A Rumor & Low Volatility Stock Suggestions - newser.com
Arrowhead Pharmaceuticals (ARWR) Is Up 5.9% After Filing for First Dual-Gene RNAi Therapy Trial – Has the Long-Term Thesis Shifted? - Sahm
Arrowhead Pharma stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Buy Rating at HC Wainwright - MarketBeat
RBC Raises Price Target on Arrowhead Pharmaceuticals to $45 From $38, Keeps Outperform, Speculative Risk - MarketScreener
HC Wainwright & Co. Reiterates Arrowhead Pharmaceuticals (ARWR) Buy Recommendation - Nasdaq
Arrowhead Pharma (ARWR) Analyst Rating Update: HC Wainwright & C - GuruFocus
Arrowhead Pharmaceuticals Hits New 52-Week High of $39.42 - Markets Mojo
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - BioSpace
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNA - PharmiWeb.com
Arrowhead Pharmaceuticals Hits New 52-Week High of $36.24 - Markets Mojo
RNAi: The Benefits Of Shooting The Messenger - Seeking Alpha
Arrowhead Pharmaceuticals And Wave Life Sciences: RNAi Is Getting Into Obesity (NASDAQ:WVE) - Seeking Alpha
Arrowhead Pharmaceuticals files CTA for investigational Aro-Dimer-PA - MarketScreener
Arrowhead files for approval of dual-target RNAi therapy for heart disease - Investing.com Nigeria
What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You - simplywall.st
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 12-Month HighStill a Buy? - MarketBeat
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):